In the latest trading session,, 1.09 million CorMedix Inc (NASDAQ:CRMD) shares changed hands as the company’s beta touched 1.61. With the company’s most recent per share price at $14.81 changing hands around $0.46 or 3.21% at last look, the market valuation stands at $1.00B. CRMD’s last price was a premium, traded about 2.36% off its 52-week high of $14.46. The share price had its 52-week low at $3.61, which suggests the last value was 75.62% up since then. When we look at CorMedix Inc’s average trading volume, we note the 10-day average is 1.45 million shares, with the 3-month average coming to 1.93 million.
Analysts gave the CorMedix Inc (CRMD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 1 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended CRMD as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. CorMedix Inc’s EPS for the current quarter is expected to be 0.12.
CorMedix Inc (NASDAQ:CRMD) trade information
Instantly CRMD is in green as seen in intraday trades today. With action 17.45%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 82.84%, with the 5-day performance at 17.45% in the green. However, in the 30-day time frame, CorMedix Inc (NASDAQ:CRMD) is 27.02% up. Looking at the short shares, we see there were 8.45 million shares sold at short interest cover period of 3.87 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need a downside of -64.56% from its recent market value. According to analyst projections, CRMD’s forecast low is 9 with 9 as the target high. To hit the forecast high, the stock’s price needs a 39.23% surge from its current level, while the stock would need to tank 39.23% for it to hit the projected low.
CorMedix Inc (CRMD) estimates and forecasts
Year-over-year growth is forecast to reach 231.77% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 29.88M. 6 analysts are of the opinion that CorMedix Inc’s revenue for the current quarter will be 35.75M. The company’s revenue for the corresponding quarters a year ago was 806.12k and 11.46M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 3,606.46%. The estimates for the next quarter sales put growth at 212.07%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 29.80%. The 2025 estimates are for CorMedix Inc earnings to increase by 365.00%.
CRMD Dividends
CorMedix Inc is expected to release its next quarterly earnings report on 2025-May-05.
CorMedix Inc (NASDAQ:CRMD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.19% of CorMedix Inc shares while 37.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 37.54%. There are 37.09% institutions holding the CorMedix Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 6.167% of the shares, roughly 3.55 million CRMD shares worth $15.39 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.0373% or 2.9 million shares worth $12.57 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . With 1.98 shares estimated at $29.66 million under it, the former controlled 2.92% of total outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held about 2.21% of the shares, roughly 1.5 shares worth around $22.44 million.
